BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, October 6, 2024
Breaking News: BioWorld celebrates nine wins at 2024 APEX Awards
See today's BioWorld Science
Home
» Oral opaganib delivers statistically significant increase in survival time in in vivo Ebola virus study
To read the full story,
subscribe
or
sign in
.
Infection
Oral opaganib delivers statistically significant increase in survival time in in vivo Ebola virus study
Oct. 4, 2023
No Comments
Redhill Biopharma Ltd. has announced a survival benefit with its oral sphingosine kinase-2 (SPHK2) selective inhibitor opaganib (ABC-294640) in an in vivo Ebola virus study.
BioWorld Science
Infection